ORTEXORTEX News
Tracking DT? Get live short interest, options flow, and signals on ORTEX.Sign up free →
DT
Trader NoteDT

Analysts lift targets as Dynatrace lags its peers

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 21 Oct 2026, 20:23

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

DT slipped 1.3% over the past week to $63.64, a notable underperformance against a median gain of 4.6% for its eight closest software peers, yet the Street chose the same moment to raise price targets across the board.

The analyst activity this week is the most pointed data in the snapshot. Truist Securities and BTIG both lifted targets on October 21, with BTIG moving from $62 to $73 and Truist from $60 to $70, both maintaining Buy ratings. That follows RBC Capital taking its target from $59 to $73 on October 12 and Barclays moving to $71 from $60 on October 13. Needham upgraded from Hold to Buy in mid-September. The direction of travel is uniformly upward, and the mean price target now sits at $63.38, almost exactly in line with the current price. That tight gap between the consensus target and the share price, despite a wave of upward revisions, tells you the stock has already absorbed much of the re-rating the Street is projecting. Bulls point to over 1,000 enterprise customers now monitoring AI and LLM workloads, annualised logs consumption approaching $200 million after doubling in two quarters, and the Arize acquisition adding around $40 million of ARR. Bears worry that competitive pressure from Datadog and others, combined with long sales cycles and the complexity of cross-selling into new buying centres, could stall ARR acceleration precisely when the valuation demands it.

Short positioning is not the story here, but it has moved enough to mention. Short interest ran up sharply through mid-October, peaking near 16.3 million shares around October 13 to 15, before retreating to 14.8 million shares, or roughly 4.9% of the free float. The one-week change is a decline of 4.4%, which suggests the buildup from September was opportunistic rather than a conviction short. Borrow conditions remain loose throughout: cost to borrow is 0.43%, one of the lowest readings in the trailing 30 days, and availability has widened back to 1,673%, meaning there are more than 16 shares available to lend for every share already borrowed. There is no squeeze pressure here. Options sentiment is the more interesting lean: the put/call ratio dropped to 0.19 on October 20, well below its 20-day average of 0.30 and close to its 52-week low of 0.13. That is about 1.5 standard deviations below the mean, pointing to unusually heavy call-side activity relative to puts. Options traders are positioned for upside into the November 3 earnings date, not hedging for disappointment.

The ownership picture carries one flag worth noting. Pictet Asset Management filed a Schedule 13D/A on September 25, the most recent of six filings since January, disclosing a stake that has edged down from 5.0% to 4.9% of shares. A Schedule 13D signals activist intent, and Pictet's presence on that register is notable even as the position has been trimmed slightly below the 5% disclosure threshold. As the standard caveat applies: 13D/G stakes are event-driven around that threshold, and a holder dropping below 5% may exit without any further filing. Starboard Value, a more familiar activist name, appears in the top-holder list with 8.9 million shares as of June 30, its entire position apparently opened in that quarter. BlackRock remains the largest holder at 12.1% as of September 30, adding 1.7 million shares in the period. Insider activity is routine: the only open-market transaction with meaningful size in recent months was the CTO's September 18 sale of 50,000 shares at $57.21 under a pre-arranged 10b5-1 plan, a planned disposal rather than a discretionary signal.

The most recent earnings prints have been broadly positive. The last three events produced first-day moves of approximately 6.7%, 1.4% and 6.9%, with the five-day returns more mixed. The pattern is a stock that tends to gap up on the day but gives back some ground over the following week. The next report is on November 3, thirteen days away. With the consensus price target sitting essentially at the current share price after a string of upgrades, the key question at that print is whether ARR growth and net expansion rates are accelerating fast enough to justify another leg of analyst target-lifting, or whether the Street's re-rating is already complete.

Stocks in this article

See the live data behind this article on ORTEX.

Open DT on ORTEX →

How this article was generated

Generated
21 Oct 2026, 20:31
Data as of
21 Oct 2026, 20:23
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.